Dr. Garnett joined a panel of distinguished speakers to discuss the use of next-generation patient-derived tumour organoids to model patient responses to therapy. His presentation showcased the use of high-fidelity cancer models that accurately reflect patient tumours, and their application for drug efficacy testing and CRISPR genetic screens. Dr. Mathew Garnett is Co-founder and Chief Scientific Officer of Mosaic Therapeutics.
We are a cancer therapeutics company using advanced computational methods and next-generation cancer models to find new synthetic-lethal cancer targets. Our main mission is to tackle cancers with substantial unmet need by reinventing target discovery. We have active programmes across a variety of cancer indications and disease biology fields and we are seeking strategic alliances with pharma companies who wish to leverage our world-leading data and platforms.
Born out of pioneering research at the Wellcome Sanger Institute and anchored around a proprietary database that has seen 20 years of tuning and development, our tools and know-how will provide our partners with an unparalleled complement of world-leading capabilities.
For media and editorial enquiries, please email: email@example.com